



ASX ANNOUNCEMENT

9 January 2013

25 Per Cent Dose Sales Growth in Second Quarter

Sirtex Medical Limited (ASX: SRX) today announced dose sales of its SIR-Spheres[®] microspheres targeted radioactive liver cancer treatment grew 25 per cent for the quarter ended 31 December 2012 compared to the previous corresponding period.

Dose sales during the second quarter, compared to the same period last year, grew in all regions. The US achieved dose sales growth of 29 per cent, Europe, Middle East and Africa (EMEA) achieved growth of 11 per cent, and Asia Pacific achieved growth of 37 per cent. Dose Sales are a key measure of the company's business performance and Sirtex has now reported 34 consecutive quarters of sales growth since 2004.

Sirtex Chief Executive Officer, Gilman Wong said, "I am pleased with this result. All four quarters during the 2012 calendar year were very strong and have set a very high benchmark for the 2013 quarters. However, I am confident that our growth performance of the last five years will be maintained.

Sirtex's prime focus continues to be the implementation of our *2020Vision* strategy with appropriate investments being made by the company in sales and marketing, manufacturing, clinical studies and research to ensure Sirtex achieves its future potential."

For further information please contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
City PR
(02) 9267 4511